Prelude Therapeutics Inc
(NAS:PRLD)
$
2.37
-0.18 (-7.06%)
Market Cap: 130.41 Mil
Enterprise Value: -21.65 Mil
PE Ratio: 0
PB Ratio: 0.72
GF Score: 40/100 Prelude Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 05:30PM GMT
Release Date Price:
$6.4
(+3.90%)
Robert Burns
H.C. Wainwright & Co., LLC - Moderator
Thank you for joining our next fireside chat. I'm Robert Burns, Managing Director and Senior Biotech Analyst at H.C. Wainwright. I'm now joined by Kris Vaddi, the CEO of Prelude Therapeutics. Kris, thank you for being here today.
Kris Vaddi
Prelude Therapeutics Incorporated - CEO, Founder, Director
Thank you, thank you for the opportunity to join the conference.
Robert Burns
H.C. Wainwright & Co., LLC - Moderator
Always, always. So for those who may be unfamiliar with Prelude and its pipeline and story, why don't you provide some of the high-level overview as to Prelude as a company?
Kris Vaddi
Prelude Therapeutics Incorporated - CEO, Founder, Director
Absolutely, absolutely. So Prelude is a precision oncology company that really founded on the basis of discovering and developing very high quality small molecule therapeutics for patients who really need them. And over the past five to six years, we've really
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot